Johnson & Johnson J&J is betting its experimental psoriasis pill, Icotyde, will become one of its most lucrative drugs ever, with analysts projecting peak annual sales of $5 billion. The drug, an oral treatment for moderate to severe plaque psoriasis, is seen as a potential blockbuster that could accelerate J&J’s revenue growth in the coming years. Shares of J&J rose nearly 2% after the company highlighted Icotyde’s promise during its investor day presentation on Tuesday.

The pharmaceutical giant is positioning Icotyde as a direct competitor to existing biologics like Humira, which has faced biosimilar competition, and other oral treatments such as Pfizer’s Cibinqo. Unlike injectable biologics, Icotyde offers a convenient pill form, which could appeal to patients and physicians alike. Analysts from Leerink Partners and Barclays have ranked Icotyde among J&J’s top future revenue drivers, estimating it could become the company’s fourth-largest drug by 2030.

J&J’s pipeline strategy focuses on oral alternatives

J&J’s push for Icotyde reflects a broader shift in its pipeline strategy toward oral medications, particularly in immunology. The company is aiming to reduce reliance on injectable biologics, which face price pressures and patent expirations. Icotyde targets a market dominated by costly injectables, offering a more accessible treatment option for the estimated 8 million Americans with psoriasis. Investors are closely watching the drug’s clinical data, with phase 3 trial results expected in mid-2024.

The drug’s potential was a key topic during J&J’s investor day, where executives emphasized its role in the company’s long-term growth plans. J&J’s chief financial officer, Joseph Wolk, noted that Icotyde could fill a gap in the psoriasis treatment landscape, especially for patients who prefer oral medications. The company is also exploring additional indications for Icotyde, including psoriatic arthritis, which could further expand its market reach.

Regulatory and competitive risks loom

Despite the optimism, Icotyde faces significant hurdles before hitting the market. The U.S. Food and Drug Administration FDA is expected to decide on approval by late 2025 or early 2026, and the drug will need to demonstrate superior efficacy or safety compared to existing treatments to justify its potential price tag. Analysts warn that competition from other oral psoriasis drugs, such as AbbVie’s Skyrizi and Novartis’s Cosentyx, could limit Icotyde’s market share.

J&J’s ability to price Icotyde competitively will also be critical. The company has not yet disclosed its pricing strategy, but analysts expect it to target a premium price given its oral formulation and strong clinical data. If approved, Icotyde could become a cornerstone of J&J’s immunology portfolio, helping offset revenue losses from patent expirations on top-selling drugs like Stelara.

Investors will be watching closely as J&J advances Icotyde through late-stage trials and the regulatory process. The drug’s success could redefine the company’s growth trajectory and reshape the psoriasis treatment market, where oral alternatives remain in high demand. Failure to meet expectations, however, could force J&J to reassess its pipeline strategy and investor confidence.

The broader implications of Icotyde’s potential success extend beyond J&J. The drug’s approval could accelerate a shift toward oral therapies in immunology, reducing reliance on biologics and biosimilars. For patients, it could mean greater access to effective treatments at potentially lower costs. The outcome of Icotyde’s regulatory review will be a bellwether for the future of psoriasis treatment.

What You Need to Know

  • Source: CNBC
  • Published: May 16, 2026 at 12:33 UTC
  • Category: Business
  • Topics: #cnbc · #finance · #economy · #investors · #icotyde · #johnson-&-johnson-psoriasis-pill

Read the Full Story

This is a curated summary. For the complete article, original data, quotes and full analysis:

Read the full story on CNBC →

All reporting rights belong to the respective author(s) at CNBC. GlobalBR News summarizes publicly available content to help readers discover the most relevant global news.

Curated by GlobalBR News · May 16, 2026

🇧🇷 Resumo em Português

A Johnson & Johnson (J&J) acende um alerta no mercado farmacêutico ao projetar que sua pílula experimental para psoríase, o Icotyde, possa atingir vendas globais de até US$ 5 bilhões no pico, colocando o medicamento entre os maiores sucessos da gigante americana.

O lançamento do Icotyde representa uma esperança não só para os mais de 125 milhões de pessoas no mundo com psoríase — doença crônica que afeta diretamente a qualidade de vida — mas também uma jogada estratégica para o Brasil, onde cerca de 3 milhões de pacientes convivem com a condição. Com a previsão de patentes e preços competitivos, o medicamento poderiaabaratear tratamentos atuais no SUS e planos de saúde, além de impulsionar a já relevante indústria farmacêutica nacional, que busca inovações em doenças autoimunes. A chegada de uma pílula oral, mais prática que injeções ou pomadas, pode ser um divisor de águas em um país onde o acesso a terapias inovadoras ainda enfrenta barreiras burocráticas e financeiras.

A expectativa é que a Anvisa analise rapidamente o Icotyde, enquanto concorrentes como a Pfizer e a Novartis já testam alternativas semelhantes — a corrida pelo mercado de psoríase mal começou.

🇪🇸 Resumen en Español

La farmacéutica Johnson & Johnson apunta alto con su nueva pastilla contra la psoriasis, Icotyde, que podría alcanzar ventas pico de 5.000 millones de dólares, según las previsiones de los analistas. Este fármaco experimental, diseñado para competir con tratamientos biológicos ya establecidos, podría revolucionar el mercado de enfermedades autoinmunes, donde las opciones orales hasta ahora han tenido un papel limitado.

El lanzamiento de Icotyde llega en un momento clave para el sector, ya que la psoriasis afecta a más de 125 millones de personas en el mundo, con una demanda creciente de terapias más accesibles y menos invasivas que las inyecciones o infusiones. Para los pacientes hispanohablantes, especialmente en países con sistemas sanitarios con recursos limitados, un medicamento oral eficaz y de administración sencilla podría significar una mejora significativa en su calidad de vida. Además, si J&J logra posicionar Icotyde como alternativa de referencia, podría presionar a los precios de otros tratamientos, beneficiando no solo a los usuarios, sino también a los sistemas de salud pública que destinan grandes partidas presupuestarias a estas enfermedades crónicas.